NCT04676646
Study to Assess Efficacy and Safety of SZC for the Management of High Potassium in Patients With Symptomatic HFrEF Receiving Spironolactone
See it on ClinicalTrials.gov ↗203 people
25.6%
74.4%
52 womenmiddle line = equal numbers151 men
- Phase
- PHASE4
- Paid for by
- AstraZeneca
- Finished
- 2024-07-15
- Health conditions
- Hyperkalaemia, Heart Failure With Reduced Ejection Fraction
- Who could join
- Anyone
- Ages
- 18 Years – 130 Years
- Average age
- mean 70.9 Years
- Age 65+
- 75.4%
- Weight (BMI)
- Not reported
- Pregnancy recorded
- Not reported
- Menopause recorded
- Not reported
- Results shown by sex
- Not split by sex
- Race
- White 91.1% · Black / African American 4.9% · Other 3.9% · Asian 0% · Native Hawaiian / Pacific Islander 0% · American Indian / Alaska Native 0% · Not reported 0%
Women left out
- No heart disease
Women with heart disease, heart rhythm problems or a past heart attack were turned away.
“Heart failure due to restrictive cardiomyopathy, active myocarditis, constrictive pericarditis, hypertrophic (obstructive) cardiomyopathy, or severe stenotic valve disease as a primary cause of HF”
Study titles and rules are shown in their original English.